Companies
MedChemExpress LLC (MCE)
Products
MedChemExpress - Model TT-232 - ...

MedChemExpress - Model TT-232 - 147159-51-1

TT-232 (CAP-232), a somatostatin derivative, is a peptide SSTR1/SSTR4 agonist. TT-232 inhibits cancer cell proliferation and induces apoptosis. TT-232 is also a broad-spectrum anti-inflammatory and analgesic agent[1][2][4].

TT-232

MCE China：TT-232

Brand：MedChemExpress (MCE)

Cat. No.HY-105172

CAS：147159-51-1

Synonyms：CAP-232; TLN-232

Purity：98.27%

Storage：Sealed storage, away from moisture and light, under nitrogen Powder -80°C 2 years -20°C 1 year *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)

Shipping：Room temperature in continental US; may vary elsewhere.

Description：TT-232 (CAP-232), a somatostatin derivative, is a peptide SSTR1/SSTR4 agonist. TT-232 inhibits cancer cell proliferation and induces apoptosis. TT-232 is also a broad-spectrum anti-inflammatory and analgesic agent.

In Vitro：TT-232 (10 μg/mL, 48 h) induces apoptosis in human colon (HT-29 and SW620), pancreatic (818), leukemia (K-562), melanoma (WM 938/B, M-1 and EP) and lymphoma (HT-58) tumor cell lines[1]. TT-232 (20-30 μg/mL, 24 h) shows antiproliferative effect on various human tumor cell lines[2].

In Vivo：TT-232 (15-750 μg/kg/day, twice a day) inhibits tumor growth in mice transplanted with Colon 26 cell[2]. TT-232 (0.6 or 15 μg/kg s.c or i.p.) shows antitumor effect on P-388 rodent lymphocytic leukemia tumor mice[3]. TT-232 (7.5-20 μg/kg, i.v.) inhibits Carrageenin-induced paw oedema in rats[4].

IC50 & Target：SSTR1 SSTR4

References：

[1]. Szende B, et al. TT-232: a somatostatin structural derivative as a potent antitumor drug candidate. Anticancer Drugs. 2003 Sep;14(8):585-8. [Content Brief]

[2]. Kéri G, et al. A tumor-selective somatostatin analog (TT-232) with strong in vitro and in vivo antitumor activity. Proc Natl Acad Sci U S A. 1996 Oct 29;93(22):12513-8. [Content Brief]

[3]. Tejeda M, et al. Growth inhibitory effect of the somatostatin structural derivative (TT-232) on leukemia models. Anticancer Res. 2005 Jan-Feb;25(1A):325-30. [Content Brief]

[4]. Pintér E, et al. Pharmacological characterisation of the somatostatin analogue TT-232: effects on neurogenic and non-neurogenic inflammation and neuropathic hyperalgesia. Naunyn Schmiedebergs Arch Pharmacol. 2002 Aug;366(2):142-50. [Content Brief]

Brand introduction:
•   MCE (MedChemExpress) has a global exclusive compound library of more than 200 kinds, and we are committed to providing the most comprehensive range of high-quality small molecule active compounds for scientific research customers around the world；
•   More than 50,000 highly selective inhibitors and agonists are involved in various popular signaling pathways and disease areas；
•   The products cover a variety of recombinant proteins, peptides, commonly used kits, more PROTAC, ADC and other characteristic products, widely used in new drug research and development, life science and other scientific research projects；
•   Provide virtual screening, ion channel screening, metabolomics analysis detection analysis, drug screening and other professional technical services；
•   It has a professional experimental center and strict quality control and verification system；
•   Provide LC/MS, NMR, HPLC, chiral analysis, elemental analysis and other quality inspection reports to ensure the high purity and high quality of products；
•   The biological activity of the products has been verified by the experiments of customers in various countries；
•   A variety of top journals such as Nature, Cell, Science and pharmaceutical patents have included the scientific research results of MCE customers；
•   Our professional team tracks the latest pharmaceutical and life science research and provides you with the latest active compounds in the world；
•   It has established long-term cooperation with the world's major pharmaceutical companies and well-known scientific research institutions。